A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients

Clinical trial NCT05824871 · RECRUITING

Trial details

NCT number: NCT05824871
Sponsor: Shanghai Jiatan Pharmatech Co., Ltd
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Rifampin-Resistant Pulmonary Tuberculosis Tuberculosis, Multidrug-Resistant (MDR-TB)

Start date: 2022-09-02
Primary completion: 2025-12-22
Enrollment: 450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.